Nairametrics
  • Home
  • Exclusives
    • Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Ranking & Reviews
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
  • Economy
    • Macro-Economic News
    • Get Data
  • General News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
  • Home
  • Exclusives
    • Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Ranking & Reviews
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
  • Economy
    • Macro-Economic News
    • Get Data
  • General News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
Nairametrics
No Result
View All Result
Home Industries Corporate deals

AstraZeneca set to buy Alexion for $39 billion

Adeyemi Adebayo by Adeyemi Adebayo
December 14, 2020
in Corporate deals, Spotlight
AstraZeneca set to buy Alexion for $39 billion
Share on FacebookShare on TwitterShare on Linkedin

Britain’s AstraZeneca has agreed to buy U.S. drugmaker, Alexion Pharmaceuticals, for $39 billion in its largest-ever deal.

England-based AstraZeneca PLC, which is involved in one of the efforts to develop a COVID-19 vaccine, said on Saturday, that it’s using a combination of cash and shares for the acquisition of Boston-based Alexion Pharmaceuticals Inc.

READ: COVID-19: Moderna vaccine 94.5% effective against virus

The purchase will enable the company to diversify away from its fast-growing cancer business, in a bet on rare-disease and immunology drugs.

The deal comes in a week that AstraZeneca said it was conducting further research to confirm whether its COVID-19 vaccine could be 90% effective, potentially slowing its rollout, and as a rival shot from Pfizer was launched in Britain and approved for use in the United States.

READ: Moderna vaccine certified to protect monkeys against Coronavirus during study

AstraZeneca and Oxford University have jointly developed a coronavirus vaccine that British and Canadian regulators are assessing, alongside a rival effort by U.S. drugmaker, Pfizer and Germany’s BioNTech that has already earned some emergency approvals, and another by U.S. biotechnology company, Moderna.

READ: Biggest online food delivery company makes debut at New York Stock Exchange

The British company said on Saturday that Alexion shareholders would receive $60 in cash and about $115 worth of equity per share – either in AstraZeneca’s UK-traded ordinary shares or in dollar-denominated American Depositary Shares.

The British firm said the boards of both companies had approved the deal, which is expected to close in the third quarter of 2021.

READ: COVID-19: EU to buy up to 300million doses of BioNTech-Pfizer’s COVID-19 vaccine

What they are saying

  • AstraZeneca Chief Executive, Pascal Soriot said, “It is a tremendous opportunity for us to accelerate our development in immunology, getting into a new segment of disease, a new segment of physicians, and patients we haven’t been able to cover so far.”
  • Speaking on an analyst call, Soriot said the deal should put to rest speculation he was on his way out, as he was determined to stay on board to see the strategic benefits of the transaction delivered.
  • Soriot also told reporters the deal was the result of exclusive talks and no competitive bidder was involved.
  • AstraZeneca Finance Chief, Marc Dunoyer, said a capital increase for the equity component of the transaction would take place on closure of the deal.
  • On AstraZeneca’s COVID-19 vaccine, Soriot said it wasn’t yet clear if the company would need results from a U.S. clinical trial before filing for approval with U.S. regulators.
  • Assuming positive results from that trial, the company should be able to submit the vaccine to U.S. regulators within the next six weeks, he added.

READ: PayPal, Square make top 10 list of most valuable U.S banks

What you should know

  • AstraZeneca was once seen as leading the race to develop a COVID-19 vaccine, but has fallen behind Pfizer and its partner BioNTech, as well as Moderna, whose shots have shown greater efficacy in late-stage clinical trials.
  • Alexion’s best-selling drug is Soliris, used against a range of rare immune disorders including paroxysmal nocturnal hemoglobinuria (PNH), which causes anaemia and blood clots, and whose revenue rose 3.6% in the first nine months to $3 billion.
  • AstraZeneca hopes that an improved version of Soliris called Ultomiris has an even larger market potential. It expects more growth from introducing the target’s rare-disease treatments to China and other emerging markets.
  • Worried about competition heating up, Hedge fund and activist investor, Elliott Management, has urged Alexion to seek a buyer and in May spoke out publicly.
  • Elliott first invested in Alexion in 2017, when the share price was only slightly lower than Friday’s close of $120.98. Elliott did not immediately respond to a request for comment.
  • AstraZeneca said it expected the deal to immediately boost core earnings and to deliver pretax synergy gains of around $500million per year. It also expects around $650million in one-time cash costs during the three years following completion.

READ: Covid-19: AstraZeneca resumes final stage trials for its vaccine after initial halt

Related

Tags: AlexionAstraZeneca

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Access Bank
Bankers Committee
Flowmono

Bfpeer
Mega Millions
FCMB
Ikeja Electrics
Zenith CEX
Kwakol Markets
First bank





    Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

    Recent News

    • EFCC arrests Accountant General of the Federation, Ahmed Idris, over alleged N80 billion fraud
    • NGX ends trading day bearish as market cap dips by N83 billion 
    • Lagos embarks on clampdown of Okada riders in Lekki, to continue tomorrow

    Follow us on social media:

    Recent News

    Nigeria’s N24.9 trillion debt not a problem – Finance Minister

    EFCC arrests Accountant General of the Federation, Ahmed Idris, over alleged N80 billion fraud

    May 16, 2022
    Nigerian stocks on Monday, March 15, 2021, closed the trading session with the Bearish note. The All-Share Index (ASI) dropped by 0.22% to settle at 38,561.84 index points almost doubling the loss of Friday last week., UPDC, ACADEMY, Others lead gainers as Market Cap grow by N2.54 billion, Nigerian Bourse close positive as Market Capitalization grew N24.92 billion

    NGX ends trading day bearish as market cap dips by N83 billion 

    May 16, 2022
    • ABOUT US
    • CONTACT US
    • PRODUCTS
    • ANDROID APP
    • iOS APP
    • DISCLAIMER
    • CAREERS
    • PRIVACY POLICY

    © 2022 Nairametrics

    No Result
    View All Result
    • Home
    • Exclusives
      • Analysis
      • Corporate Stories
      • Interviews
      • Investigations
      • Ranking & Reviews
    • Markets
      • Cryptos
      • Commodities
      • Equities
        • Dividends
        • Stock Market
      • Fixed Income
      • Market Views
    • Industries
      • Company News
      • Consumer Goods
      • Content Partners
      • Corporate deals
      • Corporate Press Releases
      • Energy
      • Entertainment
      • Financial Services
      • Hospitality & Travel
      • Manufacturing
    • Economy
      • Macro-Economic News
      • Get Data
    • General News
    • Financial Literacy
      • Career tips
      • Personal Finance
    • Lifestyle
      • Billionaire Watch
      • Profiles
    • Opinions
      • Blurb
      • Op-Eds

    © 2022 Nairametrics

    Social Media Auto Publish Powered By : XYZScripts.com